Compare Amgen, Inc. (AMGN) vs Cincinnati Financial Corporation (CINF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Cincinnati Financial Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Cincinnati Financial Corporation trades at $180.5 (market cap $27.73B). The key difference: Amgen, Inc. is far larger — about 7.1× Cincinnati Financial Corporation's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | CINF | |
|---|---|---|
Market Cap | $196.12B | $27.73B |
Sector | Health | Financials |
52-Week High | $388.16 | $192.03 |
52-Week Low | $271.18 | $145.80 |
Enterprise Value | $241.41B | $27.41B |
Dividend Yield | 2.77% | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CINF trades at $179.28, up 2.19% today, near its consensus price target of $185.75. The stock shows strong fundamentals with a P/E of 10.25, net income margin of 21.33%, and consistent earnings beats in recent quarters. Technical indicators are bearish overall, with the current price near the pivot point of $178. Recent news highlights a scheduled Q2 2026 earnings webcast and a 65-year dividend streak, with a $0.94 dividend paid in July 2026.
Outlook remains positive due to valuation appeal and earnings momentum, but risks include technical bearish signals and exposure to catastrophe losses. Revenue growth is steady, projected to reach $12.9B in 2026, supporting a bullish analyst consensus despite mixed technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →
